Европска Унија - Мелтешки - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - patiromer sorbitex calcium - iperkalemija - - mediċini għal-kura tal-iperkalimja u ' l-iperphosphatemija - veltassa huwa indikat għall-kura ta 'iperkalimja fl-adulti.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

ablynx nv - caplacizumab - purpura, purpura - aġenti antitrombotiċi - cablivi huwa indikat għall-kura ta ' adulti li qegħdin jesperjenzaw episodju ta miksuba purpura tromboċitopenika trombotika (attp), flimkien mal-plażma tal-kambju u l-immunosoppressjoni.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

akcea therapeutics ireland limited - inotersen sodium - amyloidosis - drogi oħra tas-sistema nervuża - it-trattament tal-fażi 1 jew l-istadju 2 polinewropatija f'pazjenti adulti b'ereditarji transthyretin amilojdożi (hattr).

Европска Унија - Мелтешки - EMA (European Medicines Agency)

amgen europe bv - sotorasib - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.